Curaleaf Holdings (CURLF) Total Non-Current Liabilities (2019 - 2025)
Curaleaf Holdings (CURLF) recorded quarterly Total Non-Current Liabilities of $1.3 billion in Q4 2025, up 1.85% quarter-over-quarter from $1.3 billion in Q4 2024, and up 1.85% on a YoY basis from $1.3 billion in Q4 2024.
Curaleaf Holdings (CURLF) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends
Curaleaf Holdings' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $1.3 billion for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 1.85% year-over-year to $1.3 billion; the TTM figure through Dec 2025 stood at $1.3 billion (up 1.85% YoY), while the FY2025 annual figure was $1.3 billion, up 1.85% from the prior year.
- Total Non-Current Liabilities was $1.3 billion for Q4 2025 at Curaleaf Holdings, up from $1.3 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $2.0 billion in Q3 2023 to a low of -$6.6 billion in Q1 2022.
- Historically, Total Non-Current Liabilities has averaged $866.1 million across 5 years, with a median of $1.4 billion in 2023.
- Biggest YoY gain for Total Non-Current Liabilities was 23719.32% in 2022; the steepest drop was 716.6% in 2022.
- A 5-year view of Total Non-Current Liabilities shows it stood at $4.2 million in 2021, then jumped by 23719.32% to $1.0 billion in 2022, then soared by 33.87% to $1.4 billion in 2023, then fell by 4.82% to $1.3 billion in 2024, then grew by 1.85% to $1.3 billion in 2025.
- The last three Total Non-Current Liabilities figures came in at $1.3 billion (Q4 2025), $1.3 billion (Q4 2024), and $1.6 billion (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.13 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 1.81 Bn |
| 10 | Curaleaf Holdings | - | - | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.31 Bn |
| Dec 31, 2024 | 1.29 Bn |
| Sep 30, 2024 | 1.61 Bn |
| Jun 30, 2024 | 1.64 Bn |
| Dec 31, 2023 | 1.35 Bn |
| Sep 30, 2023 | 2.01 Bn |
| Jun 30, 2023 | 1.99 Bn |
| Dec 31, 2022 | 1.01 Bn |
| Sep 30, 2022 | 1.83 Bn |
| Jun 30, 2022 | 1.73 Bn |
| Mar 31, 2022 | -6.61 Bn |
| Dec 31, 2021 | 4.24 Mn |
| Sep 30, 2021 | 1.41 Bn |
| Jun 30, 2021 | 1.34 Bn |
| Mar 31, 2021 | 1.07 Bn |
| Dec 31, 2020 | 982.82 Mn |
| Sep 30, 2020 | 973.34 Mn |
| Dec 31, 2019 | 300.86 Mn |